If you are on a GLP-1 medication and something feels off, you are not alone. And if you are deciding whether to start one, side effects are probably the first thing you want a straight answer on. Nausea, constipation, fatigue and other stomach symptoms are the most common reasons people call us, before they start and after, and they are also the most predictable side effects of this class of medicines.
Our physicians do not leave you to tough it out. When nausea is the problem, they can prescribe a short course of ondansetron (Zofran) to get you through the first weeks or a dose increase, and every patient gets practical diet guidance: smaller, protein-first meals, less fat and sugar in the days after an injection, and steady fluids. Together with a slower titration, that combination resolves most side effects without stopping treatment.
This page covers what the clinical trials and FDA prescribing information actually show for brand-name tirzepatide and brand-name semaglutide: how often each side effect happens, when it usually starts, how long it tends to last, and what helps. We also explain when a symptom is a reason to call a clinician the same day.
Most side effects are mild to moderate and fade as your body adjusts. The biggest factor you can control is how fast your dose goes up. That is the part our physicians manage.
GLP-1 side effects at a glance
| Side effect | How common in trials (drug vs placebo) | Typical timing | What usually helps |
|---|---|---|---|
| Nausea | Brand-name tirzepatide 25% to 29% vs 8%; brand-name semaglutide 44% vs 16% | First weeks and after each dose increase; median episode about 8 days (semaglutide) | Smaller meals, stop at first fullness, avoid greasy food, slower titration |
| Diarrhea | Brand-name tirzepatide 19% to 23% vs 8%; brand-name semaglutide 30% vs 16% | Early in treatment; median episode about 3 days (semaglutide) | Fluids with electrolytes, bland foods, limit fat and sugar alcohols |
| Vomiting | Brand-name tirzepatide 8% to 13% vs 2%; brand-name semaglutide 24% vs 6% | During dose escalation; median episode about 2 days (semaglutide) | Small sips of fluid, smaller meals, hold the next dose increase, call us if persistent |
| Constipation | Brand-name tirzepatide 11% to 17% vs 5%; brand-name semaglutide 24% vs 11% | Can start later and last longer; median episode about 47 days (semaglutide) | Water, gradual fiber, movement, an osmotic laxative if your clinician agrees |
| Headache | Brand-name semaglutide 14% vs 10% | Often early, linked to low intake or fluids | Hydration, regular small meals, sleep |
| Fatigue | Brand-name tirzepatide 5% to 7% vs 3%; brand-name semaglutide 11% vs 5% | First weeks, around dose changes | Enough protein and fluids, steady meals, rest |
| Hair loss | Brand-name tirzepatide 4% to 5% vs 1%; brand-name semaglutide 3% vs 1% | Usually 2 to 4 months into weight loss | Adequate protein, check iron and other labs if heavy, patience |
| Injection site reactions | Brand-name tirzepatide 6% to 8% vs 2%; brand-name semaglutide 1.4% vs 1% | Within a day or two of a dose | Rotate sites, room-temperature injection, clean technique |
| Dizziness | Brand-name tirzepatide 4% to 5% vs 2%; brand-name semaglutide 8% vs 4% | Early, especially with low fluids or blood pressure medicines | Fluids, stand up slowly, review blood pressure medicines |
| Reflux and burping | Brand-name tirzepatide reflux 4% to 5% vs 2%, burping 4% to 5% vs 1%; brand-name semaglutide burping 7% vs under 1% | After meals, worse after dose increases | Smaller meals, no eating within 3 hours of bed, limit carbonation |
| Decreased appetite | Brand-name tirzepatide 5% to 11% vs 1% | Within days of starting | Planned protein-first meals, do not skip fluids |
| Pancreatitis, gallbladder disease, kidney injury | Each about 1% or less | Any time, more often with rapid weight loss or dehydration | Know the warning signs below and seek care promptly |
Ranges show the 5 mg to 15 mg doses in the brand-name tirzepatide weight-management trials and the 2.4 mg dose in the brand-name semaglutide weight-management trials, as reported in each FDA label. Type 2 diabetes figures come from the brand-name tirzepatide diabetes trials. Duration figures come from a pooled analysis of the STEP 1 to 3 semaglutide trials. Your experience may differ.
If you haven’t started yet: what to expect in the first two months
Side effects are front-loaded. The first month on the starting dose and the week or two after each increase are when most people notice symptoms, and most of those symptoms are mild. Three things make the start easier: beginning at the lowest dose, moving up no faster than every four weeks, and eating smaller meals from day one rather than waiting until nausea tells you to. A physician who can slow the schedule when you need it is the difference between a rough first month and a manageable one.
If you have a history of pancreatitis, gallbladder disease, medullary thyroid cancer, or MEN 2, tell your provider before anything is prescribed; those are the histories that rule GLP-1s out.
Why side effects are worst in the first 4 to 8 weeks and after each dose increase
GLP-1 medicines slow how quickly your stomach empties and act on appetite centers in the brain. The brand-name tirzepatide label notes that the slowing of stomach emptying is largest after the first dose and diminishes over time. Your body adapts, which is why symptoms usually ease at a steady dose.
Each dose increase restarts part of that adjustment. In the brand-name tirzepatide trials, the majority of nausea, vomiting and diarrhea occurred during dose escalation and decreased over time. In the pooled STEP semaglutide trials, the share of people with nausea peaked around week 20, the end of the escalation period, and declined afterward. In the STEP 1 to 3 trials, GI side effects led 4.3% of people on semaglutide 2.4 mg to stop treatment, versus 0.7% on placebo, and most of those discontinuations happened during the 16-week dose-escalation period.
This is the core reason the FDA labels start low and step up slowly. Brand-name tirzepatide starts at 2.5 mg weekly for 4 weeks and increases in 2.5 mg steps no sooner than every 4 weeks. Brand-name semaglutide starts at 0.25 mg weekly and steps up every 4 weeks, and its label says to consider delaying an increase by 4 weeks if a dose is not tolerated.
Nausea
Nausea is the most common GLP-1 side effect. In the pooled brand-name tirzepatide weight-management trials, it affected 25% of adults at 5 mg, 29% at 10 mg and 28% at 15 mg, compared with 8% on placebo. On brand-name semaglutide 2.4 mg, it affected 44%, compared with 16% on placebo. In the type 2 diabetes trials, rates were lower: 12% to 18% on brand-name tirzepatide and 15.8% to 20.3% on brand-name semaglutide.
It usually feels like early fullness or queasiness after eating, rather than a stomach bug. In a pooled analysis of the STEP 1 to 3 trials, an individual nausea episode on semaglutide 2.4 mg lasted a median of 8 days. In that analysis, 98.1% of GI events on semaglutide were mild to moderate and 99.5% were non-serious.
If nausea keeps you from eating or drinking, that is a dosing conversation, not something to push through.
- Eat smaller portions and stop at the first sign of fullness.
- Avoid greasy, fried and very sweet foods, especially in the 2 to 3 days after your injection.
- Sip fluids between meals rather than drinking large amounts with food.
- Try bland options such as crackers, rice, broth, yogurt or ginger tea.
- Ask us about holding your current dose longer before the next increase.
- For short-term relief, your clinician may prescribe an antinausea medicine such as ondansetron.
Vomiting
Vomiting is less common than nausea but more important to watch. In the brand-name tirzepatide trials it affected 8% to 13% of adults depending on dose, versus 2% on placebo. On brand-name semaglutide 2.4 mg it affected 24%, versus 6% on placebo. Median episodes in the STEP analysis were short, about 2 days.
Repeated vomiting can lead to dehydration, which is the main path to the kidney problems described later on this page. If you take birth control pills, note that the brand-name tirzepatide label advises adding a backup non-oral method for 4 weeks after starting and after each dose increase, because absorption of oral contraceptives can be affected.
- Take small, frequent sips of water or an electrolyte drink.
- Pause solid food for a few hours, then restart with small, bland portions.
- Do not take your next dose increase until vomiting has fully settled.
- Call us if you cannot keep fluids down for 24 hours, or right away if you see blood or have severe abdominal pain.
Diarrhea
Diarrhea affected 19% to 23% of adults in the brand-name tirzepatide trials (8% on placebo) and 30% on brand-name semaglutide 2.4 mg (16% on placebo). It tends to appear early in treatment. In the STEP analysis, the median diarrhea episode lasted about 3 days.
The main risk is fluid loss, especially if diarrhea comes with vomiting or poor intake.
- Replace fluids with water plus an electrolyte drink.
- Limit high-fat meals, dairy if it bothers you, and sugar-free products that contain sugar alcohols.
- Choose simple foods such as bananas, rice, oatmeal and toast for a day or two.
- Tell us if diarrhea lasts more than a few days, or if you feel dizzy or are urinating much less.
Constipation
Constipation affected 11% to 17% of adults in the brand-name tirzepatide trials (5% on placebo) and 24% on brand-name semaglutide 2.4 mg (11% on placebo). Unlike nausea, it can show up later and linger. In the STEP analysis, the median constipation episode lasted about 47 days, much longer than other GI side effects.
Eating less food and drinking less fluid both contribute. Postmarketing reports for tirzepatide include severe constipation and intestinal obstruction, so severe pain, bloating or vomiting with no bowel movement needs prompt evaluation.
- Drink water steadily through the day.
- Add fiber gradually from vegetables, berries, beans or a psyllium supplement.
- Walk daily, even briefly.
- Ask your clinician about an osmotic laxative such as polyethylene glycol if diet changes are not enough.
Headaches
Headache affected 14% of adults on brand-name semaglutide 2.4 mg, compared with 10% on placebo, and it is listed among brand-name semaglutide’s most common adverse reactions. In our experience, headaches often travel with low fluid intake, skipped meals or a sudden drop in caffeine.
- Keep fluids steady, especially on days with nausea or diarrhea.
- Eat small regular meals rather than going long stretches without food.
- Keep caffeine intake consistent.
- Seek care right away for a sudden, severe headache or a headache with vision changes, weakness or confusion.
Fatigue and tiredness
Fatigue affected 5% to 7% of adults in the brand-name tirzepatide trials (3% on placebo) and 11% on brand-name semaglutide 2.4 mg (5% on placebo). It is usually most noticeable in the first weeks and around dose changes, when people are eating noticeably less.
Persistent exhaustion is worth a check. Low intake, dehydration, low blood pressure and, in people with diabetes, low blood sugar can all contribute.
- Aim for protein at every meal, even when portions are small.
- Keep fluids up and do not skip meals entirely.
- Protect your sleep.
- Tell us if fatigue is severe or comes with dizziness or fainting.
Hair loss
Hair loss is now listed among the common adverse reactions on both brand-name labels. It was reported in 4% to 5% of adults on brand-name tirzepatide (1% on placebo) and 3% on brand-name semaglutide 2.4 mg (1% on placebo). In the brand-name tirzepatide trials it was far more common in women than men (7.1% vs 0.5%), and no one on brand-name tirzepatide stopped treatment because of it.
The brand-name tirzepatide label states that hair loss in its trials was associated with weight reduction. The usual pattern is telogen effluvium: diffuse shedding that begins a few months after a physical stressor such as rapid weight loss. The same shedding is seen after bariatric surgery and crash dieting, and a 2026 systematic review concluded that weight-loss dynamics, rather than the drug class alone, appear to drive the risk. Telogen effluvium is usually temporary, though regrowth can take months.
- Prioritize protein and an overall balanced diet during weight loss.
- Ask about checking iron, vitamin D, thyroid and other labs if shedding is heavy.
- Let us know early, since a slower titration may reduce the pace of change.
- See a dermatologist for patchy hair loss, scalp symptoms, or shedding that lasts more than 6 months.
Injection site reactions
Redness, itching, bruising or a small lump where you inject affected 6% to 8% of adults in the brand-name tirzepatide trials (2% on placebo) and 1.4% on brand-name semaglutide (1% on placebo). These reactions are usually mild and resolve within a few days.
- Rotate sites between the abdomen, thigh and upper arm with every dose.
- Let the medication reach room temperature before injecting, if your instructions allow.
- Use a new needle every time.
- Seek care for spreading redness, warmth, pus or fever.
Dizziness
Dizziness affected 4% to 5% of adults in the brand-name tirzepatide trials (2% on placebo) and 8% on brand-name semaglutide 2.4 mg (4% on placebo). Low blood pressure was reported in 1.6% of brand-name tirzepatide patients versus 0.1% on placebo, and it was more frequent in people already taking blood pressure medicines.
- Drink enough fluids, especially with GI symptoms.
- Stand up slowly.
- Tell us about all blood pressure medicines; your doses may need review as your weight changes.
- Seek urgent care for fainting, chest pain or a racing heartbeat.
Acid reflux and burping
Slower stomach emptying can push stomach contents upward. Reflux affected 4% to 5% of adults on brand-name tirzepatide (2% on placebo), and burping affected 4% to 5% (1% on placebo). On brand-name semaglutide 2.4 mg, burping affected 7% (under 1% on placebo) and indigestion 9% (3% on placebo). Some patients describe “sulfur burps” after heavy or high-protein meals.
- Eat smaller meals and finish eating at least 3 hours before bed.
- Limit carbonated drinks, alcohol, spicy and fatty foods.
- Raise the head of your bed if symptoms are worse at night.
- Ask your clinician whether an over-the-counter antacid or acid reducer is appropriate for you.
Decreased appetite and food aversion
Reduced appetite is part of how these medicines work, but it can go too far. On brand-name tirzepatide, decreased appetite was reported in 5% to 11% of adults (1% on placebo). Some people develop aversions to foods they used to enjoy, or forget to eat.
The concern is not eating enough protein, fluids and nutrients to stay well.
- Plan meals instead of waiting to feel hungry.
- Eat protein first, then vegetables, then starches.
- Use liquid options such as protein shakes or soups when solid food feels hard.
- Tell us if you are routinely eating very little; we can adjust your dose.
“Ozempic face” and loose skin
“Ozempic face” is not a medical diagnosis or a labeled side effect. It is a popular term for facial volume loss and looser skin that can follow significant weight loss. Mayo Clinic notes that nothing in these medications specifically targets facial fat; the face changes because body fat decreases overall.
The same changes happen after weight loss from diet or surgery. Age, genetics and how quickly weight comes off all play a role.
- A gradual, physician-managed pace of weight change.
- Adequate protein and resistance exercise to support muscle.
- Sun protection and good skin care.
- A board-certified dermatologist or plastic surgeon if you want to discuss cosmetic options.
Serious but rare side effects
These are uncommon, but everyone on a GLP-1 should know the warning signs.
- Pancreatitis.
- In the pooled brand-name tirzepatide weight-management trials, adjudicated acute pancreatitis occurred in 0.2% of patients on brand-name tirzepatide and 0.2% on placebo. Both brand-name labels warn about pancreatitis, including rare severe forms. Warning sign: persistent, severe abdominal pain, sometimes spreading to the back, with or without vomiting. Stop your dose and seek care immediately.
- Gallbladder disease.
- In the brand-name tirzepatide trials, gallstones occurred in 1.1% of patients (1% on placebo) and gallbladder inflammation in 0.7% (0.2% on placebo). On brand-name semaglutide, gallstones occurred in 1.6% (0.7% on placebo). The brand-name tirzepatide label notes these events were associated with weight reduction. Warning signs: pain in the upper right abdomen, fever, yellowing of the skin or eyes, or clay-colored stools.
- Low blood sugar (hypoglycemia).
- The risk is mainly in people who also take insulin or a sulfonylurea. In a brand-name tirzepatide trial of adults with type 2 diabetes, low blood sugar occurred in 4.2% of patients, rising to 10.3% in those also taking a sulfonylurea. In adults without diabetes it was rare, reported in 0.3% of brand-name tirzepatide patients. If you take diabetes medicines, your prescriber may need to lower them.
- Thyroid C-cell tumor boxed warning.
- Tirzepatide and semaglutide caused thyroid C-cell tumors in rodents. It is unknown whether they cause these tumors, including medullary thyroid carcinoma (MTC), in humans. These medicines are contraindicated if you or a family member has had MTC, or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Report a lump in the neck, trouble swallowing, persistent hoarseness or shortness of breath.
- Kidney injury from dehydration.
- Acute kidney injury has been reported, mostly in people who became dehydrated from nausea, vomiting or diarrhea. In the brand-name tirzepatide trials, it was reported in 0.5% of patients versus 0.2% on placebo. Staying hydrated during GI symptoms is the best prevention.
- Mood changes.
- In January 2026, after reviewing 91 placebo-controlled trials with 107,910 patients and a claims cohort comparing more than 2.2 million new users of GLP-1 medicines with users of SGLT2 inhibitors, the FDA found no increased risk of suicidal thoughts or behavior with GLP-1 medicines and asked the makers of the brand-name GLP-1 medicines to remove that warning from their labels. We still ask about mood at every check-in, because weight, eating and medication changes can affect how people feel. If you ever have thoughts of harming yourself, call or text 988 or go to the nearest emergency room.
- Other label warnings.
- Serious allergic reactions are rare but possible. These medicines are not recommended for people with severe gastroparesis. Tell any surgeon or anesthesiologist that you take a GLP-1 before a procedure, because slower stomach emptying can raise the risk of aspiration under anesthesia. Stop the medicine if you become pregnant.
Why physician-managed dosing matters
The label schedule is a minimum pace, not a requirement to move up every 4 weeks. Both labels build in flexibility: the brand-name semaglutide label allows delaying an increase by 4 weeks, and the brand-name tirzepatide label allows choosing a lower maintenance dose if a higher one is not tolerated. Trial investigators observed fewer GI side effects with tirzepatide’s lower starting dose and smaller steps than with faster escalation in earlier studies.
Here is how our physicians use that flexibility:
- Slower escalation. If you are still adjusting, we stay at your current dose longer before stepping up.
- Holding a dose. If symptoms flare after an increase, we can keep you at that level until they settle.
- Stepping back down. If a dose is not working for your body, we can return to the last dose you tolerated well.
- Splitting a weekly dose. For select patients on compounded vials, a physician may split the weekly amount into two smaller injections. This approach was not studied in the pivotal trials, so we use it only when clinically appropriate and with clear written instructions.
- Restarting carefully. The brand-name semaglutide label advises restarting at a lower dose after 2 or more missed doses to reduce GI side effects. We follow the same principle for missed doses.
The FDA has warned about adverse events tied to dosing errors and to compounded GLP-1 doses or escalation schedules beyond what the approved labels describe. Our physicians do not escalate faster than the label pace.
Brand-name vs compounded: do side effects differ?
Brand-name tirzepatide and brand-name semaglutide are FDA-approved. Their side-effect rates come from large clinical trials.
Compounded tirzepatide and compounded semaglutide are prepared by state-licensed 503A pharmacies from a physician’s prescription for an individual patient. Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness or quality before they are dispensed, and they were not the products studied in the SURMOUNT, SURPASS, STEP or SUSTAIN trials. No head-to-head trials have compared side-effect rates between compounded and brand-name products, so we cannot tell you that side effects will be the same, better or worse.
Some compounding pharmacies add vitamin B6 (pyridoxine) or vitamin B12 to GLP-1 preparations. B6 has a long history of use for pregnancy-related nausea, but its effect on GLP-1 nausea has not been established in clinical trials, and additives do not make a compounded product FDA-approved. The FDA has also warned about products made with salt forms such as semaglutide sodium or semaglutide acetate, which it considers different active ingredients from those in the approved drugs. Ask any provider which pharmacy prepares your medication and what it contains.
When to seek care immediately
- Severe abdominal pain that does not go away, with or without vomiting, or pain spreading to your back
- Vomiting you cannot stop, or vomiting blood
- Signs of dehydration: very little urine, dark urine, dizziness when standing, or confusion
- Swelling of the face, lips, tongue or throat, trouble breathing, or a severe rash
- Fainting, chest pain or a very fast heartbeat
- Severe low blood sugar symptoms, such as shaking, sweating, confusion or passing out
- Thoughts of harming yourself (you can also call or text 988)
Contact your Precision Telemed care team the same day for: vomiting or diarrhea lasting more than 24 hours, upper right abdominal pain or yellow skin or eyes, a new lump in your neck or hoarseness that does not go away, no bowel movement with bloating and pain, or any side effect that keeps you from eating or drinking normally.
Frequently asked questions
No. In the brand-name tirzepatide weight-management trials, roughly 1 in 4 adults reported nausea and about 1 in 8 reported vomiting, which means most did not. Side effects are more likely at higher doses and during increases, which is why starting low and stepping up slowly matters.
Yes. GLP-1 medicines are not habit-forming and can be stopped at any time. Most people never need to; a dose hold or a step back usually resolves the problem. If you do stop, talk to your provider first so it is done on purpose rather than by skipping doses.
For most people, the stomach side effects are strongest in the first 4 to 8 weeks and for a week or two after each dose increase, then ease at a steady dose. In pooled semaglutide trial data, a nausea episode lasted a median of 8 days, diarrhea 3 days and vomiting 2 days. Constipation lasted longer, a median of 47 days. If symptoms are not improving, your dose plan may need adjusting. How long do semaglutide side effects last?
Not necessarily. In pooled STEP 1 to 3 trial data, average weight change with semaglutide 2.4 mg was 9.6% to 17.1% in people without GI side effects and 11.4% to 17.7% in people with them, and less than 1 percentage point of the difference from placebo was explained by GI side effects. A similar analysis of the tirzepatide SURMOUNT trials found GI side effects had only a slight relationship to weight change. Feeling sick is not a goal, and having no side effects is not a sign that the medicine isn’t working.
Many clinicians prescribe ondansetron (Zofran) for short-term nausea on GLP-1 medicines, and clinical trial protocols have used it for that purpose. It requires a prescription, and it has side effects of its own, including constipation, so your clinician will review your other medicines first. Experts recommend using it for short periods rather than to allow a faster dose increase. If you need it often, a slower titration is usually the better fix.
Hair loss was reported in 4% to 5% of adults on brand-name tirzepatide in clinical trials, compared with 1% on placebo, and it was much more common in women. The label states it was associated with weight reduction. It is usually telogen effluvium, a temporary shedding that also happens after other causes of rapid weight loss.
Hair loss was reported in 3% of adults on brand-name semaglutide 2.4 mg, compared with 1% on placebo. As with tirzepatide, the most likely mechanism is telogen effluvium linked to weight loss.
Each step up brings a stronger effect on stomach emptying and appetite, and your body needs time to adjust again. Trial data for both tirzepatide and semaglutide show GI side effects cluster during escalation. If an increase hits hard, ask your physician about holding or stepping back.
Small portions of bland, lower-fat foods: broth-based soups, rice, toast, crackers, yogurt, eggs, lean proteins and cooked vegetables. Stop eating at the first sign of fullness, and avoid large, greasy or very sweet meals, especially in the first few days after your injection.
There are no clinical trials comparing side-effect rates between compounded and brand-name tirzepatide. Compounded medications are not FDA-approved. The trial data on this page come from the brand-name products, and we use them as a guide for monitoring all patients.
Do not stop on your own for mild symptoms; call your clinician to discuss a dose adjustment first. Stop and seek care immediately for severe abdominal pain, vomiting you cannot stop, signs of an allergic reaction, or any of the emergency symptoms listed above.
Mainly in people who also take insulin or a sulfonylurea. In one brand-name tirzepatide trial in adults with type 2 diabetes, low blood sugar occurred in 10.3% of those also taking a sulfonylurea, compared with 2.1% of those who were not. In people without diabetes it is uncommon.
About this page
Medical Director at Precision Telemed. Trained at Lake Erie College of Osteopathic Medicine, Dr. Palumbo leads clinical oversight across all weight loss and wellness programs.
Precision Telemed is a physician-led, LegitScript-certified telehealth practice serving patients in all 50 states. We are not a pharmacy. Prescriptions are filled by licensed 503A compounding pharmacies.
This page was written using FDA prescribing information and peer-reviewed clinical trial publications listed below. It is reviewed when labels or major evidence change. Last reviewed: October 6, 2026.
Medical disclaimer: This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Always talk with your physician about your symptoms and medicines. Prescription required. A licensed physician determines eligibility after a medical evaluation. Compounded medications, including compounded tirzepatide and compounded semaglutide, are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality. Individual results and side effects vary. If you think you are having a medical emergency, call 911.
References
- Eli Lilly and Company. ZEPBOUND (tirzepatide) injection. Full Prescribing Information. Revised August 2026. uspl.lilly.com/zepbound
- U.S. National Library of Medicine, DailyMed. ZEPBOUND (tirzepatide) label. dailymed.nlm.nih.gov
- Eli Lilly and Company. MOUNJARO (tirzepatide) injection. Full Prescribing Information. uspl.lilly.com/mounjaro
- Novo Nordisk. WEGOVY (semaglutide) injection and tablets. Prescribing Information, revised June 2026. DailyMed. dailymed.nlm.nih.gov
- Novo Nordisk. WEGOVY (semaglutide) injection. Prescribing Information (Table 3 adverse reactions). accessdata.fda.gov
- Novo Nordisk. OZEMPIC (semaglutide) injection. Prescribing Information. DailyMed. dailymed.nlm.nih.gov
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216. nejm.org
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002. nejm.org
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385:503-515. nejm.org
- Patel H, Khunti K, Rodbard HW, et al. Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials. Diabetes Obes Metab. 2024. dom-pubs.onlinelibrary.wiley.com
- Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022;24(1):94-105. dom-pubs.onlinelibrary.wiley.com
- Rubino DM, et al. Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials. Diabetes Obes Metab. 2025. dom-pubs.onlinelibrary.wiley.com
- Gorgojo-Martínez JJ, Mezquita-Raya P, Carretero-Gómez J, et al. Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with GLP-1 Receptor Agonists: A Multidisciplinary Expert Consensus. J Clin Med. 2023;12(1):145. ncbi.nlm.nih.gov
- Gupta AK, Teasell EM, Economopoulos V, Mirmirani P. GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling. 2026. journals.sagepub.com
- U.S. Food and Drug Administration. FDA Requests Removal of Suicidal Behavior and Ideation Warning from GLP-1 RA Medications. Drug Safety Communication, January 13, 2026. fda.gov
- U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. fda.gov
- U.S. Food and Drug Administration. FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs. FDA Statement, February 6, 2026. fda.gov
- Mayo Clinic Press. Let’s stop using the term “Ozempic face.” mcpress.mayoclinic.org
- “Ozempic Face” in Plastic Surgery: A Systematic Review of the Literature on GLP-1 Receptor Agonist Mediated Weight Loss and Analysis of Public Perceptions. ncbi.nlm.nih.gov
- diaTribe. 7 Tips for Navigating Nausea on a GLP-1 Medicine. diatribe.org